Top

European Journal of Nuclear Medicine and Molecular Imaging

Published in:

Open Access 01-03-2022 | NSCLC | Guidelines

Joint EANM/SNMMI/ESTRO practice recommendations for the use of 2-[¹⁸F]FDG PET/CT external beam radiation treatment planning in lung cancer V1.0

Authors: Sofia C. Vaz, Judit A. Adam, Roberto C. Delgado Bolton, Pierre Vera, Wouter van Elmpt, Ken Herrmann, Rodney J. Hicks, Yolande Lievens, Andrea Santos, Heiko Schöder, Bernard Dubray, Dimitris Visvikis, Esther G. C. Troost, Lioe-Fee de Geus-Oei

Published in: European Journal of Nuclear Medicine and Molecular Imaging | Issue 4/2022

Abstract

Purpose

2-[¹⁸F]FDG PET/CT is of utmost importance for radiation treatment (RT) planning and response monitoring in lung cancer patients, in both non-small and small cell lung cancer (NSCLC and SCLC). This topic has been addressed in guidelines composed by experts within the field of radiation oncology. However, up to present, there is no procedural guideline on this subject, with involvement of the nuclear medicine societies.

Methods

A literature review was performed, followed by a discussion between a multidisciplinary team of experts in the different fields involved in the RT planning of lung cancer, in order to guide clinical management. The project was led by experts of the two nuclear medicine societies (EANM and SNMMI) and radiation oncology (ESTRO).

Results and conclusion

This guideline results from a joint and dynamic collaboration between the relevant disciplines for this topic. It provides a worldwide, state of the art, and multidisciplinary guide to 2-[¹⁸F]FDG PET/CT RT planning in NSCLC and SCLC. These practical recommendations describe applicable updates for existing clinical practices, highlight potential flaws, and provide solutions to overcome these as well. Finally, the recent developments considered for future application are also reviewed.

WHO. https://www.paho.org/hq/index.php?option=com_docman&view=download&category_slug=4-cancer-country-profiles-2020&alias=51561-global-cancer-profile-2020&Itemid=270&lang=en. Accessed Jan 2021

Rahib L, Wehner MR, Matrisian LM, Nead KT. Estimated projection of US cancer incidence and death to 2040. JAMA Network Open 2021; https://doi.org/10.1001/jamanetworkopen.2021.4708.

Duma N, Santana-Davila R, Molina JR. Non-small cell lung cancer: epidemiology, screening, diagnosis, and treatment. Mayo Clin Proc 2019; https://doi.org/10.1016/j.mayocp.2019.01.013.

Detterbeck FC, Boffa DJ, Kim AW, Tanoue LT. The eighth edition lung cancer stage classification. Chest 2017; https://doi.org/10.1016/j.chest.2016.10.010.

Ettinger DS, Wood DE, Aisner DL, Akerley W, Bauman JR, Bharat A, et al. NCCN guidelines insights: non-small cell lung cancer, Version 2.2021. J Natl Compr Canc Netw 2021; https://doi.org/10.6004/jnccn.2021.0013.

Nicholson AG, Chansky K, Crowley J, Beyruti R, Kubota K, Turrisi A, et al. The International Association for the Study of Lung Cancer Lung Cancer Staging Project: proposals for the revision of the clinical and pathologic staging of small cell lung cancer in the Forthcoming Eighth Edition of the TNM Classification for Lung Cancer. J Thorac Oncol 2016; https://doi.org/10.1016/j.jtho.2015.10.008.

Howlader N NA, Krapcho M, Miller D, Brest A, Yu M, Ruhl J, Tatalovich Z, Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA SEER Cancer Statistics Review, 1975-2017, National Cancer Institute. 2019.

Le Pechoux C, Faivre-Finn C, Ramella S, McDonald F, Manapov F, Putora PM, et al. ESTRO ACROP guidelines for target volume definition in the thoracic radiation treatment of small cell lung cancer. Radiother Oncol 2020; https://doi.org/10.1016/j.radonc.2020.07.012.

Postmus PE, Kerr KM, Oudkerk M, Senan S, Waller DA, Vansteenkiste J, et al. Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2017; https://doi.org/10.1093/annonc/mdx222.

10.

Früh M, De Ruysscher D, Popat S, Crinò L, Peters S, Felip E. Small-cell lung cancer (SCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2013; https://doi.org/10.1093/annonc/mdt178.

11.

Guckenberger M, Andratschke N, Dieckmann K, Hoogeman MS, Hoyer M, Hurkmans C, et al. ESTRO ACROP consensus guideline on implementation and practice of stereotactic body radiotherapy for peripherally located early stage non-small cell lung cancer. Radiother Oncol 2017; https://doi.org/10.1016/j.radonc.2017.05.012.

12.

Nestle U, De Ruysscher D, Ricardi U, Geets X, Belderbos J, Pöttgen C, et al. ESTRO ACROP guidelines for target volume definition in the treatment of locally advanced non-small cell lung cancer. Radiother Oncol 2018; https://doi.org/10.1016/j.radonc.2018.02.023.

13.

De Ruysscher D, Faivre-Finn C, Nestle U, Hurkmans CW, Le Péchoux C, Price A, et al. European Organisation for Research and Treatment of Cancer recommendations for planning and delivery of high-dose, high-precision radiotherapy for lung cancer. J Clin Oncol 2010.

14.

Yuan S, Sun X, Li M, Yu J, Ren R, Yu Y, et al. A randomized study of involved-field irradiation versus elective nodal irradiation in combination with concurrent chemotherapy for inoperable stage III nonsmall cell lung cancer. Am J Clin Oncol 2007.

15.

Nestle U, Schimek-Jasch T, Kremp S, Schaefer-Schuler A, Mix M, Küsters A, et al. Imaging-based target volume reduction in chemoradiotherapy for locally advanced non-small-cell lung cancer (PET-Plan): a multicentre, open-label, randomised, controlled trial. Lancet Oncol 2020; https://doi.org/10.1016/s1470-2045(20)30013-9

16.

Martinussen HMA, Reymen B, Wanders R, Troost EGC, Dingemans A-MC, Öllers M, et al. Is selective nodal irradiation in non-small cell lung cancer still safe when using IMRT? Results of a prospective cohort study. Radiother Oncol 2016; https://doi.org/10.1016/j.radonc.2016.10.001.

17.

Topkan E, Ozdemir Y, Guler OC, Kucuk A, Besen AA, Mertsoylu H, et al. Comparison of involved field radiotherapy versus elective nodal irradiation in stage IIIB/C non-small-cell lung carcinoma patients treated with concurrent chemoradiotherapy: a propensity score matching study. J Oncol 2020; https://doi.org/10.1155/2020/7083149

18.

Li R, Yu L, Lin S, Wang L, Dong X, Yu L, et al. Involved field radiotherapy (IFRT) versus elective nodal irradiation (ENI) for locally advanced non-small cell lung cancer: a meta-analysis of incidence of elective nodal failure (ENF). Radiat Oncol 2016; https://doi.org/10.1186/s13014-016-0698-3

19.

Bütof R, Gumina C, Valentini C, Sommerer A, Appold S, Zips D, et al. Sites of recurrent disease and prognostic factors in SCLC patients treated with radiochemotherapy. Clinical and Translational Radiation Oncology 2017; https://doi.org/10.1016/j.ctro.2017.09.010

20.

van Loon J, De Ruysscher D, Wanders R, Boersma L, Simons J, Oellers M, et al. Selective nodal irradiation on basis of (18)FDG-PET scans in limited-disease small-cell lung cancer: a prospective study. Int J Radiat Oncol Biol Phys 2010; https://doi.org/10.1016/j.ijrobp.2009.04.075

21.

Søgaard R, Fischer BM, Mortensen J, Højgaard L, Lassen U. Preoperative staging of lung cancer with PET/CT: cost-effectiveness evaluation alongside a randomized controlled trial. Eur J Nucl Med Mol Imaging 2011; https://doi.org/10.1007/s00259-010-1703-y

22.

Liu J, Dong M, Sun X, Li W, Xing L, Yu J. Prognostic Value of 18F-FDG PET/CT in Surgical Non-Small Cell Lung Cancer: A Meta-Analysis. PLoS One 2016; https://doi.org/10.1371/journal.pone.0146195

23.

Na F, Wang J, Li C, Deng L, Xue J, Lu Y. Primary tumor standardized uptake value measured on F18-Fluorodeoxyglucose positron emission tomography is of prediction value for survival and local control in non-small-cell lung cancer receiving radiotherapy: meta-analysis. J Thorac Oncol 2014; https://doi.org/10.1097/jto.0000000000000185

24.

Usmanij EA, Geus-Oei L-Fd, Troost EGC, Peters-Bax L, van der Heijden EHFM, Kaanders JHAM, et al. <sup>18</sup>F-FDG PET early response evaluation of locally advanced non–small cell lung cancer treated with concomitant chemoradiotherapy. J Nucl Med 2013; https://doi.org/10.2967/jnumed.112.116921.

25.

Mac Manus MP, Everitt S, Bayne M, Ball D, Plumridge N, Binns D, et al. The use of fused PET/CT images for patient selection and radical radiotherapy target volume definition in patients with non-small cell lung cancer: results of a prospective study with mature survival data. Radiother Oncol 2013; https://doi.org/10.1016/j.radonc.2012.12.018

26.

Kubota K, Matsuno S, Morioka N, Adachi S, Koizumi M, Seto H, et al. Impact of FDG-PET findings on decisions regarding patient management strategies: a multicenter trial in patients with lung cancer and other types of cancer. Ann Nucl Med 2015; https://doi.org/10.1007/s12149-015-0963-9

27.

Ruben JD, Ball DL. The efficacy of PET staging for small-cell lung cancer: a systematic review and cost analysis in the Australian setting. J Thorac Oncol 2012; https://doi.org/10.1097/JTO.0b013e31824fe90a

28.

Lardinois D, Weder W, Hany TF, Kamel EM, Korom S, Seifert B, et al. Staging of non–small-cell lung cancer with integrated positron-emission tomography and computed tomography. N Engl J Med 2003; https://doi.org/10.1056/NEJMoa022136

29.

Birim O, Kappetein AP, Stijnen T, Bogers AJ. Meta-analysis of positron emission tomographic and computed tomographic imaging in detecting mediastinal lymph node metastases in nonsmall cell lung cancer. Ann Thorac Surg 2005; https://doi.org/10.1016/j.athoracsur.2004.06.041

30.

van Tinteren H, Hoekstra OS, Smit EF, van den Bergh JH, Schreurs AJ, Stallaert RA, et al. Effectiveness of positron emission tomography in the preoperative assessment of patients with suspected non-small-cell lung cancer: the PLUS multicentre randomised trial. Lancet 2002; https://doi.org/10.1016/s0140-6736(02)08352-6

31.

MacManus MP, Hicks RJ, Matthews JP, Hogg A, McKenzie AF, Wirth A, et al. High rate of detection of unsuspected distant metastases by pet in apparent stage III non-small-cell lung cancer: implications for radical radiation therapy. Int J Radiat Oncol Biol Phys 2001; https://doi.org/10.1016/s0360-3016(01)01477-8

32.

Fischer BM, Mortensen J, Langer SW, Loft A, Berthelsen AK, Petersen BI, et al. A prospective study of PET/CT in initial staging of small-cell lung cancer: comparison with CT, bone scintigraphy and bone marrow analysis. Ann Oncol 2007; https://doi.org/10.1093/annonc/mdl374

33.

Bradley JD, Dehdashti F, Mintun MA, Govindan R, Trinkaus K, Siegel BA. Positron emission tomography in limited-stage small-cell lung cancer: a prospective study. J Clin Oncol 2004; https://doi.org/10.1200/jco.2004.11.089

34.

Hong JC, Boyer MJ, Spiegel DY, Williams CD, Tong BC, Shofer SL, et al. Increasing PET use in small cell lung cancer: survival improvement and stage migration in the VA Central Cancer Registry. J Natl Compr Canc Netw 2019; https://doi.org/10.6004/jnccn.2018.7090

35.

Brink I, Schumacher T, Mix M, Ruhland S, Stoelben E, Digel W, et al. Impact of [18F]FDG-PET on the primary staging of small-cell lung cancer. Eur J Nucl Med Mol Imaging 2004; https://doi.org/10.1007/s00259-004-1606-x

36.

Martucci F, Pascale M, Valli MC, Pesce GA, Froesch P, Giovanella L, et al. Impact of 18F-FDG PET/CT in staging patients with small cell lung cancer: a systematic review and meta-analysis. Frontiers in Medicine 2020; https://doi.org/10.3389/fmed.2019.00336

37.

Kalemkerian GP. Staging and imaging of small cell lung cancer. Cancer Imaging 2012; https://doi.org/10.1102/1470-7330.2011.0036

38.

Kalade AV, Eddie Lau WF, Conron M, Wright GM, Desmond PV, Hicks RJ, et al. Endoscopic ultrasound-guided fine-needle aspiration when combined with positron emission tomography improves specificity and overall diagnostic accuracy in unexplained mediastinal lymphadenopathy and staging of non-small-cell lung cancer. Intern Med J 2008; https://doi.org/10.1111/j.1445-5994.2008.01670.x

39.

Peeters ST, Dooms C, Van Baardwijk A, Dingemans AM, Martinussen H, Vansteenkiste J, et al. Selective mediastinal node irradiation in non-small cell lung cancer in the IMRT/VMAT era: How to use E(B)US-NA information in addition to PET-CT for delineation? Radiother Oncol 2016; https://doi.org/10.1016/j.radonc.2016.05.023

40.

Vilmann P, Clementsen PF, Colella S, Siemsen M, De Leyn P, Dumonceau JM, et al. Combined endobronchial and esophageal endosonography for the diagnosis and staging of lung cancer: European Society of Gastrointestinal Endoscopy (ESGE) Guideline, in cooperation with the European Respiratory Society (ERS) and the European Society of Thoracic Surgeons (ESTS). Endoscopy 2015; https://doi.org/10.1055/s-0034-1392040

41.

Burnet NG, Thomas SJ, Burton KE, Jefferies SJ. Defining the tumour and target volumes for radiotherapy. Cancer imaging: the official publication of the International Cancer Imaging Society 2004; https://doi.org/10.1102/1470-7330.2004.0054

42.

Boellaard R, Delgado-Bolton R, Oyen WJ, Giammarile F, Tatsch K, Eschner W, et al. FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0. Eur J Nucl Med Mol Imaging 2015; https://doi.org/10.1007/s00259-014-2961-x.

43.

Jarritt PH, Carson KJ, Hounsell AR, Visvikis D. The role of PET/CT scanning in radiotherapy planning. Br J Radiol 2006; https://doi.org/10.1259/bjr/35628509

44.

Konert T, Vogel W, MacManus MP, Nestle U, Belderbos J, Grégoire V, et al. PET/CT imaging for target volume delineation in curative intent radiotherapy of non-small cell lung cancer: IAEA consensus report 2014. Radiother Oncol 2015; https://doi.org/10.1016/j.radonc.2015.03.014

45.

van Baardwijk A, Bosmans G, Boersma L, Buijsen J, Wanders S, Hochstenbag M, et al. PET-CT-based auto-contouring in non-small-cell lung cancer correlates with pathology and reduces interobserver variability in the delineation of the primary tumor and involved nodal volumes. Int J Radiat Oncol Biol Phys 2007; https://doi.org/10.1016/j.ijrobp.2006.12.067

46.

Steenbakkers RJ, Duppen JC, Fitton I, Deurloo KE, Zijp LJ, Comans EF, et al. Reduction of observer variation using matched CT-PET for lung cancer delineation: a three-dimensional analysis. Int J Radiat Oncol Biol Phys 2006; https://doi.org/10.1016/j.ijrobp.2005.06.034

47.

MacManus M, Nestle U, Rosenzweig KE, Carrio I, Messa C, Belohlavek O, et al. Use of PET and PET/CT for radiation therapy planning: IAEA expert report 2006-2007. Radiother Oncol 2009; https://doi.org/10.1016/j.radonc.2008.11.008

48.

Steenbakkers RJ, Duppen JC, Fitton I, Deurloo KE, Zijp L, Uitterhoeve AL, et al. Observer variation in target volume delineation of lung cancer related to radiation oncologist-computer interaction: a ’Big Brother’ evaluation. Radiother Oncol 2005; https://doi.org/10.1016/j.radonc.2005.09.017

49.

Yin L-J, Yu X-B, Ren Y-G, Gu G-H, Ding T-G, Lu Z. Utilization of PET-CT in target volume delineation for three-dimensional conformal radiotherapy in patients with non-small cell lung cancer and atelectasis. Multidisciplinary Respiratory Medicine 2013; https://doi.org/10.1186/2049-6958-8-21

50.

Lavrenkov K, Partridge M, Cook G, Brada M. Positron emission tomography for target volume definition in the treatment of non-small cell lung cancer. Radiother Oncol 2005; https://doi.org/10.1016/j.radonc.2005.09.016

51.

Greco C, Rosenzweig K, Cascini GL, Tamburrini O. Current status of PET/CT for tumour volume definition in radiotherapy treatment planning for non-small cell lung cancer (NSCLC). Lung Cancer 2007; https://doi.org/10.1016/j.lungcan.2007.03.020

52.

Bradley J, Bae K, Choi N, Forster K, Siegel BA, Brunetti J, et al. A phase II comparative study of gross tumor volume definition with or without PET/CT fusion in dosimetric planning for non-small-cell lung cancer (NSCLC): primary analysis of Radiation Therapy Oncology Group (RTOG) 0515. Int J Radiat Oncol Biol Phys 2012; https://doi.org/10.1016/j.ijrobp.2010.09.033

53.

Hallqvist A, Alverbratt C, Strandell A, Samuelsson O, Björkander E, Liljegren A, et al. Positron emission tomography and computed tomographic imaging (PET/CT) for dose planning purposes of thoracic radiation with curative intent in lung cancer patients: a systematic review and meta-analysis. Radiother Oncol 2017; https://doi.org/10.1016/j.radonc.2017.02.011

54.

Lopci E, Kobe C, Gnanasegaran G, Adam JA, de Geus-Oei LF. PET/CT variants and pitfalls in lung cancer and mesothelioma. Semin Nucl Med 2021; https://doi.org/10.1053/j.semnuclmed.2021.04.002

55.

Vanuytsel LJ, Vansteenkiste JF, Stroobants SG, De Leyn PR, De Wever W, Verbeken EK, et al. The impact of (18)F-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) lymph node staging on the radiation treatment volumes in patients with non-small cell lung cancer. Radiother Oncol 2000; https://doi.org/10.1016/s0167-8140(00)00138-9

56.

Videtic GM, Rice TW, Murthy S, Suh JH, Saxton JP, Adelstein DJ, et al. Utility of positron emission tomography compared with mediastinoscopy for delineating involved lymph nodes in stage III lung cancer: insights for radiotherapy planning from a surgical cohort. Int J Radiat Oncol Biol Phys 2008; https://doi.org/10.1016/j.ijrobp.2008.01.045

57.

Steinfort DP, Siva S, Leong TL, Rose M, Herath D, Antippa P, et al. Systematic endobronchial ultrasound-guided mediastinal staging versus positron emission tomography for comprehensive mediastinal staging in NSCLC before radical radiotherapy of non-small cell lung cancer: a pilot study. Medicine (Baltimore) 2016; https://doi.org/10.1097/md.0000000000002488

58.

Nestle U, Rischke HC, Eschmann SM, Holl G, Tosch M, Miederer M, et al. Improved inter-observer agreement of an expert review panel in an oncology treatment trial--Insights from a structured interventional process. Eur J Cancer 2015; https://doi.org/10.1016/j.ejca.2015.07.036

59.

Huang K, Dahele M, Senan S, Guckenberger M, Rodrigues GB, Ward A, et al. Radiographic changes after lung stereotactic ablative radiotherapy (SABR)—can we distinguish recurrence from fibrosis? A systematic review of the literature. Radiother Oncol 2012; https://doi.org/10.1016/j.radonc.2011.12.018

60.

Nakajima N, Sugawara Y, Kataoka M, Hamamoto Y, Ochi T, Sakai S, et al. Differentiation of tumor recurrence from radiation-induced pulmonary fibrosis after stereotactic ablative radiotherapy for lung cancer: characterization of 18F-FDG PET/CT findings. Ann Nucl Med 2013; https://doi.org/10.1007/s12149-012-0682-4

61.

Hoopes DJ, Tann M, Fletcher JW, Forquer JA, Lin PF, Lo SS, et al. FDG-PET and stereotactic body radiotherapy (SBRT) for stage I non-small-cell lung cancer. Lung Cancer 2007; https://doi.org/10.1016/j.lungcan.2006.12.009

62.

Matsuo Y, Nakamoto Y, Nagata Y, Shibuya K, Takayama K, Norihisa Y, et al. Characterization of FDG-PET images after stereotactic body radiation therapy for lung cancer. Radiother Oncol 2010; https://doi.org/10.1016/j.radonc.2010.04.011

63.

Larici AR, del Ciello A, Maggi F, Santoro SI, Meduri B, Valentini V, et al. Lung abnormalities at multimodality imaging after radiation therapy for non-small cell lung cancer. Radiographics 2011; https://doi.org/10.1148/rg.313105096

64.

Takeda A, Kunieda E, Fujii H, Yokosuka N, Aoki Y, Oooka Y, et al. Evaluation for local failure by 18F-FDG PET/CT in comparison with CT findings after stereotactic body radiotherapy (SBRT) for localized non-small-cell lung cancer. Lung Cancer 2013; https://doi.org/10.1016/j.lungcan.2012.11.008

65.

Mac Manus MP, Ding Z, Hogg A, Herschtal A, Binns D, Ball DL, et al. Association between pulmonary uptake of fluorodeoxyglucose detected by positron emission tomography scanning after radiation therapy for non-small-cell lung cancer and radiation pneumonitis. Int J Radiat Oncol Biol Phys 2011; https://doi.org/10.1016/j.ijrobp.2010.04.021

66.

Iravani A, Turgeon GA, Akhurst T, Callahan JW, Bressel M, Everitt SJ, et al. PET-detected pneumonitis following curative-intent chemoradiation in non-small cell lung cancer (NSCLC): recognizing patterns and assessing the impact on the predictive ability of FDG-PET/CT response assessment. Eur J Nucl Med Mol Imaging 2019; https://doi.org/10.1007/s00259-019-04388-3

67.

Yuan ST, Brown RK, Zhao L, ten Haken RK, Gross M, Cease KB, et al. Timing and intensity of changes in FDG uptake with symptomatic esophagitis during radiotherapy or chemo-radiotherapy. Radiat Oncol 2014; https://doi.org/10.1186/1748-717x-9-37

68.

Kandathil A, Sibley RC, III, Subramaniam RM. Lung cancer recurrence: (18)F-FDG PET/CT in Clinical Practice. AJR Am J Roentgenol 2019; https://doi.org/10.2214/ajr.19.21227

69.

Sheikhbahaei S, Mena E, Yanamadala A, Reddy S, Solnes LB, Wachsmann J, et al. The value of FDG PET/CT in treatment response assessment, follow-up, and surveillance of lung cancer. American Journal of Roentgenology 2016; https://doi.org/10.2214/AJR.16.16532

70.

Kitajima K, Doi H, Kanda T, Yamane T, Tsujikawa T, Kaida H, et al. Present and future roles of FDG-PET/CT imaging in the management of lung cancer. Japanese Journal of Radiology 2016; https://doi.org/10.1007/s11604-016-0546-2

71.

Wahl RL, Jacene H, Kasamon Y, Lodge MA. From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors. J Nucl Med 2009; https://doi.org/10.2967/jnumed.108.057307

72.

Sheikhbahaei S, Mena E, Marcus C, Wray R, Taghipour M, Subramaniam RM. <sup>18</sup>F-FDG PET/CT: therapy response assessment interpretation (Hopkins Criteria) and Survival Outcomes in Lung Cancer Patients. J Nucl Med 2016; https://doi.org/10.2967/jnumed.115.165480

73.

Aerts HJ, Bussink J, Oyen WJ, van Elmpt W, Folgering AM, Emans D, et al. Identification of residual metabolic-active areas within NSCLC tumours using a pre-radiotherapy FDG-PET-CT scan: a prospective validation. Lung Cancer 2012; https://doi.org/10.1016/j.lungcan.2011.06.003

74.

Shusharina N, Cho J, Sharp GC, Choi NC. Correlation of (18)F-FDG avid volumes on pre-radiation therapy and post-radiation therapy FDG PET scans in recurrent lung cancer. Int J Radiat Oncol Biol Phys 2014; https://doi.org/10.1016/j.ijrobp.2014.01.047

75.

Wang J, Wong KK, Piert M, Stanton P, Frey KA, Kong FS. Metabolic response assessment with (18)F-FDG PET/CT: inter-method comparison and prognostic significance for patients with non-small cell lung cancer. Journal of radiation oncology 2015; https://doi.org/10.1007/s13566-015-0184-9

76.

Clarke K, Taremi M, Dahele M, Freeman M, Fung S, Franks K, et al. Stereotactic body radiotherapy (SBRT) for non-small cell lung cancer (NSCLC): is FDG-PET a predictor of outcome? Radiother Oncol 2012; https://doi.org/10.1016/j.radonc.2012.04.019

77.

Berghmans T, Lievens Y, Aapro M, Baird AM, Beishon M, Calabrese F, et al. European Cancer Organisation Essential Requirements for Quality Cancer Care (ERQCC): Lung cancer. Lung Cancer 2020; https://doi.org/10.1016/j.lungcan.2020.08.017

78.

Doll C, Duncker-Rohr V, Rucker G, Mix M, MacManus M, De Ruysscher D, et al. Influence of experience and qualification on PET-based target volume delineation. When there is no expert--ask your colleague. Strahlenther Onkol 2014; https://doi.org/10.1007/s00066-014-0644-y.

79.

Fragoso Costa P, Santos A, Testanera G. An insight into the EANM technologist committee benchmark document on nuclear medicine technologists’ competencies. Eur J Nucl Med Mol Imaging 2017; https://doi.org/10.1007/s00259-017-3741-1

80.

CSC B. ACR–AAPM technical standard for medical nuclear physics performance monitoring of PET imaging equipment. 2016.

81.

RPN. EUROPEAN guidelines on medical physics expert. 2014.

82.

Delbeke D, Coleman RE, Guiberteau MJ, Brown ML, Royal HD, Siegel BA, et al. Procedure guideline for tumor imaging with 18F-FDG PET/CT 1.0. J Nucl Med 2006.

83.

Gregoire V. Is there any future in radiotherapy planning without the use of PET: unraveling the myth. Radiother Oncol 2004; https://doi.org/10.1016/j.radonc.2004.10.005

84.

Bixler A, Springer G, Lovas R. Practical aspects of radiation safety for using fluorine-18. J Nucl Med Technol 1999.

85.

Thorwarth D, Beyer T, Boellaard R, de Ruysscher D, Grgic A, Lee JA, et al. Integration of FDG-PET/CT into external beam radiation therapy planning: technical aspects and recommendations on methodological approaches. Nuklearmedizin 2012; https://doi.org/10.3413/Nukmed-0455-11-12

86.

De Ruysscher D, Faivre-Finn C, Moeller D, Nestle U, Hurkmans CW, Le Pechoux C, et al. European Organization for Research and Treatment of Cancer (EORTC) recommendations for planning and delivery of high-dose, high precision radiotherapy for lung cancer. Radiother Oncol 2017; https://doi.org/10.1016/j.radonc.2017.06.003

87.

Keall PJ, Mageras GS, Balter JM, Emery RS, Forster KM, Jiang SB, et al. The management of respiratory motion in radiation oncology report of AAPM Task Group 76a). Med Phys 2006; https://doi.org/10.1118/1.2349696

88.

Nehmeh SA, Erdi YE, Pan T, Pevsner A, Rosenzweig KE, Yorke E, et al. Four-dimensional (4D) PET/CT imaging of the thorax. Med Phys 2004; https://doi.org/10.1118/1.1809778

89.

Chirindel A, Adebahr S, Schuster D, Schimek-Jasch T, Schanne DH, Nemer U, et al. Impact of 4D-(18)FDG-PET/CT imaging on target volume delineation in SBRT patients with central versus peripheral lung tumors. Multi-reader comparative study. Radiother Oncol 2015; https://doi.org/10.1016/j.radonc.2015.05.019

90.

Sindoni A, Minutoli F, Pontoriero A, Iatì G, Baldari S, Pergolizzi S. Usefulness of four dimensional (4D) PET/CT imaging in the evaluation of thoracic lesions and in radiotherapy planning: Review of the literature. Lung Cancer 2016; https://doi.org/10.1016/j.lungcan.2016.03.019

91.

Kesner AL, Chung JH, Lind KE, Kwak JJ, Lynch D, Burckhardt D, et al. Validation of software gating: a practical technology for respiratory motion correction in PET. Radiology 2016; https://doi.org/10.1148/radiol.2016152105

92.

Callahan J, Kron T, Siva S, Simoens N, Edgar A, Everitt S, et al. Geographic miss of lung tumours due to respiratory motion: a comparison of 3D vs 4D PET/CT defined target volumes. Radiat Oncol 2014; https://doi.org/10.1186/s13014-014-0291-6

93.

Adebahr S, Collette S, Shash E, Lambrecht M, Le Pechoux C, Faivre-Finn C, et al. LungTech, an EORTC Phase II trial of stereotactic body radiotherapy for centrally located lung tumours: a clinical perspective. Br J Radiol 2015; https://doi.org/10.1259/bjr.20150036

94.

Lambrecht M, Melidis C, Sonke J-J, Adebahr S, Boellaard R, Verheij M, et al. Lungtech, a phase II EORTC trial of SBRT for centrally located lung tumours — a clinical physics perspective. Radiation Oncology 2016; https://doi.org/10.1186/s13014-015-0567-5

95.

Yang S-N, Chiang W-C, Chou K-T, Zhang G, Huang T-C. Planning lung radiotherapy incorporating motion freeze PET/CT imaging. Applied Sciences 2018.

96.

Huang TC, Chou KT, Wang YC, Zhang G. Motion freeze for respiration motion correction in PET/CT: a preliminary investigation with lung cancer patient data. Biomed Res Int 2014; https://doi.org/10.1155/2014/167491

97.

van der Vos CS, Grootjans W, Meeuwis AP, Slump CH, Oyen WJ, de Geus-Oei LF, et al. Comparison of a free-breathing CT and an expiratory breath-hold CT with regard to spatial alignment of amplitude-based respiratory-gated PET and CT images. J Nucl Med Technol 2014; https://doi.org/10.2967/jnmt.114.145748

98.

van der Vos CS, Meeuwis APW, Grootjans W, Geus-Oei LF, Visser EP. Improving the spatial alignment in PET/CT using amplitude-based respiration-gated PET and patient-specific breathing-instructed CT. J Nucl Med Technol 2019; https://doi.org/10.2967/jnmt.118.215970

99.

van der Vos CS, Grootjans W, Osborne DR, Meeuwis AP, Hamill JJ, Acuff S, et al. Improving the spatial alignment in PET/CT using amplitude-based respiration-gated PET and respiration-triggered CT. J Nucl Med 2015; https://doi.org/10.2967/jnumed.115.163055

100.

Grootjans W, Tixier F, van der Vos CS, Vriens D, Le Rest CC, Bussink J, et al. The impact of optimal respiratory gating and image noise on evaluation of intratumor heterogeneity on 18F-FDG PET imaging of lung cancer. J Nucl Med 2016; https://doi.org/10.2967/jnumed.116.173112

101.

Kesner AL, Meier JG, Burckhardt DD, Schwartz J, Lynch DA. Data-driven optimal binning for respiratory motion management in PET. Med Phys 2018; https://doi.org/10.1002/mp.12651

102.

Tumpa TR, Acuff SN, Gregor J, Lee S, Hu D, Osborne DR. Respiratory motion correction using a novel positron emission particle tracking technique: a framework towards individual lesion-based motion correction. Annual International Conference of the IEEE Engineering in Medicine and Biology Society IEEE Engineering in Medicine and Biology Society Annual International Conference 2018; https://doi.org/10.1109/embc.2018.8513486

103.

Kesner A, Schmidtlein CR, Kuntner C. Real-time data-driven motion correction in PET. EJNMMI Physics 2019; https://doi.org/10.1186/s40658-018-0240-9

104.

Zaidi H, El Naqa I. PET-guided delineation of radiation therapy treatment volumes: a survey of image segmentation techniques. Eur J Nucl Med Mol Imaging 2010; https://doi.org/10.1007/s00259-010-1423-3

105.

Hatt M, Lee JA, Schmidtlein CR, Naqa IE, Caldwell C, De Bernardi E, et al. Classification and evaluation strategies of auto-segmentation approaches for PET: Report of AAPM task group No. 211. Med Phys 2017; https://doi.org/10.1002/mp.12124.

106.

Hatt M, Laurent B, Ouahabi A, Fayad H, Tan S, Li L, et al. The first MICCAI challenge on PET tumor segmentation. Med Image Anal 2018; https://doi.org/10.1016/j.media.2017.12.007

107.

Werner-Wasik M, Nelson AD, Choi W, Arai Y, Faulhaber PF, Kang P, et al. What is the best way to contour lung tumors on PET scans? Multiobserver validation of a gradient-based method using a NSCLC digital PET phantom. Int J Radiat Oncol Biol Phys 2012; https://doi.org/10.1016/j.ijrobp.2010.12.055

108.

Hatt M, Cheze Le Rest C, Albarghach N, Pradier O, Visvikis D. PET functional volume delineation: a robustness and repeatability study. Eur J Nucl Med Mol Imaging 2011; https://doi.org/10.1007/s00259-010-1688-6.

109.

Wang X, Cui H, Gong G, Fu Z, Zhou J, Gu J, et al. Computational delineation and quantitative heterogeneity analysis of lung tumor on 18F-FDG PET for radiation dose-escalation. Sci Rep 2018; https://doi.org/10.1038/s41598-018-28818-88

110.

Schaefer A, Nestle U, Kremp S, Hellwig D, Grgic A, Buchholz HG, et al. Multi-centre calibration of an adaptive thresholding method for PET-based delineation of tumour volumes in radiotherapy planning of lung cancer. Nuklearmedizin 2012; https://doi.org/10.3413/Nukmed-0452-11-12

111.

Geets X, Lee JA, Bol A, Lonneux M, Grégoire V. A gradient-based method for segmenting FDG-PET images: methodology and validation. Eur J Nucl Med Mol Imaging 2007; https://doi.org/10.1007/s00259-006-0363-4

112.

Yu H, Caldwell C, Mah K, Mozeg D. Coregistered FDG PET/CT-based textural characterization of head and neck cancer for radiation treatment planning. IEEE Trans Med Imaging 2009; https://doi.org/10.1109/tmi.2008.2004425

113.

Han D, Bayouth J, Song Q, Taurani A, Sonka M, Buatti J, et al. Globally optimal tumor segmentation in PET-CT images: a graph-based co-segmentation method. Inf Process Med Imaging 2011; https://doi.org/10.1007/978-3-642-22092-0_21

114.

El Naqa I, Yang D, Apte A, Khullar D, Mutic S, Zheng J, et al. Concurrent multimodality image segmentation by active contours for radiotherapy treatment planning. Med Phys 2007; https://doi.org/10.1118/1.2799886

115.

Belhassen S, Zaidi H. A novel fuzzy C-means algorithm for unsupervised heterogeneous tumor quantification in PET. Med Phys 2010; https://doi.org/10.1118/1.3301610

116.

Hatt M, Cheze le Rest C, Descourt P, Dekker A, De Ruysscher D, Oellers M, et al. Accurate automatic delineation of heterogeneous functional volumes in positron emission tomography for oncology applications. Int J Radiat Oncol Biol Phys 2010; https://doi.org/10.1016/j.ijrobp.2009.08.018.

117.

Li L, Lu W, Tan S. Variational PET/CT Tumor Co-segmentation Integrated with PET Restoration. IEEE Trans Radiat Plasma Med Sci 2020; https://doi.org/10.1109/trpms.2019.2911597

118.

Hanzouli-Ben Salah H, Lapuyade-Lahorgue J, Bert J, Benoit D, Lambin P, Van Baardwijk A, et al. A framework based on hidden Markov trees for multimodal PET/CT image co-segmentation. Med Phys 2017; https://doi.org/10.1002/mp.12531

119.

Hatt M, Tixier F, Pierce L, Kinahan PE, Le Rest CC, Visvikis D. Characterization of PET/CT images using texture analysis: the past, the present... any future? Eur J Nucl Med Mol Imaging 2017; https://doi.org/10.1007/s00259-016-3427-0.

120.

Guo Z, Li X, Huang H, Guo N, Li Q. Deep learning-based image segmentation on multimodal medical imaging. IEEE Transactions on Radiation and Plasma Medical Sciences 2019; https://doi.org/10.1109/TRPMS.2018.2890359

121.

Schaefer A, Vermandel M, Baillet C, Dewalle-Vignion AS, Modzelewski R, Vera P, et al. Impact of consensus contours from multiple PET segmentation methods on the accuracy of functional volume delineation. Eur J Nucl Med Mol Imaging 2016; https://doi.org/10.1007/s00259-015-3239-7

122.

Lam L, Suen SY. Application of majority voting to pattern recognition: an analysis of its behavior and performance. IEEE Transactions on Systems, Man, and Cybernetics - Part A: Systems and Humans 1997; https://doi.org/10.1109/3468.618255.

123.

Warfield SK, Zou KH, Wells WM. Simultaneous truth and performance level estimation (STAPLE): an algorithm for the validation of image segmentation. IEEE Trans Med Imaging 2004; https://doi.org/10.1109/tmi.2004.828354

124.

Commowick O, Akhondi-Asl A, Warfield SK. Estimating a reference standard segmentation with spatially varying performance parameters: local MAP STAPLE. IEEE Trans Med Imaging 2012; https://doi.org/10.1109/TMI.2012.2197406

125.

Berthon B, Marshall C, Evans M, Spezi E. ATLAAS: an automatic decision tree-based learning algorithm for advanced image segmentation in positron emission tomography. Phys Med Biol 2016; https://doi.org/10.1088/0031-9155/61/13/4855

126.

McGurk RJ, Bowsher J, Lee JA, Das SK. Combining multiple FDG-PET radiotherapy target segmentation methods to reduce the effect of variable performance of individual segmentation methods. Med Phys 2013; https://doi.org/10.1118/1.4793721

127.

Dewalle-Vignion A-S, Betrouni N, Baillet C, Vermandel M. Is STAPLE algorithm confident to assess segmentation methods in PET imaging? Phys Med Biol 2015; https://doi.org/10.1088/0031-9155/60/24/9473

128.

Kaalep A, Sera T, Oyen W, Krause BJ, Chiti A, Liu Y, et al. EANM/EARL FDG-PET/CT accreditation — summary results from the first 200 accredited imaging systems. Eur J Nucl Med Mol Imaging 2018; https://doi.org/10.1007/s00259-017-3853-7

129.

Aide N, Lasnon C, Veit-Haibach P, Sera T, Sattler B, Boellaard R. EANM/EARL harmonization strategies in PET quantification: from daily practice to multicentre oncological studies. Eur J Nucl Med Mol Imaging 2017; https://doi.org/10.1007/s00259-017-3740-2

130.

IEC 61223-3-5:2019 Evaluation and routine testing in medical imaging departments — Part 3-5: Acceptance and constancy tests - Imaging performance of computed tomography X-ray equipment. 2019.

131.

Busemann Sokole E, Plachcinska A, Britten A, Committee EP. Acceptance testing for nuclear medicine instrumentation. Eur J Nucl Med Mol Imaging 2010; https://doi.org/10.1007/s00259-009-1348-x

132.

Mutic S, Palta JR, Butker EK, Das IJ, Huq MS, Loo LN, et al. Quality assurance for computed-tomography simulators and the computed-tomography-simulation process: report of the AAPM Radiation Therapy Committee Task Group No. 66. Med Phys 2003; https://doi.org/10.1118/1.1609271.

133.

Seierstad T, Stranden E, Bjering K, Evensen M, Holt A, Michalsen HM, et al. Doses to nuclear technicians in a dedicated PET/CT centre utilising 18F fluorodeoxyglucose (FDG). Radiat Prot Dosimetry 2007; https://doi.org/10.1093/rpd/ncl141

134.

Costa PF, Reinhardt M, Poppe B. Occupational exposure from F-18-FDG PET/CT: implementation to routine clinical practice. Radiation protection dosimetry 2018; https://doi.org/10.1093/rpd/ncx276

135.

ACR. ACR Position Statement on Quality Control and Improvement, Safety, Infection Control and Patient Education. 2019.

136.

Ling CC, Humm J, Larson S, Amols H, Fuks Z, Leibel S, et al. Towards multidimensional radiotherapy (MD-CRT): biological imaging and biological conformality. Int J Radiat Oncol Biol Phys 2000; https://doi.org/10.1016/s0360-3016(00)00467-3

137.

Bentzen SM. Dose painting and theragnostic imaging: towards the prescription, planning and delivery of biologically targeted dose distributions in external beam radiation oncology. Cancer Treat Res 2008.

138.

Petit SF, Aerts HJ, van Loon JG, Offermann C, Houben R, Winkens B, et al. Metabolic control probability in tumour subvolumes or how to guide tumour dose redistribution in non-small cell lung cancer (NSCLC): an exploratory clinical study. Radiother Oncol 2009; https://doi.org/10.1016/j.radonc.2009.02.020

139.

Hatt M, Visvikis D. Defining radiotherapy target volumes using 18F-fluoro-deoxy-glucose positron emission tomography/computed tomography: still a Pandora’s box?: in regard to Devic et al. (Int J Radiat Oncol Biol Phys 2010). Int J Radiat Oncol Biol Phys 2010; https://doi.org/10.1016/j.ijrobp.2010.08.002.

140.

van Elmpt W, De Ruysscher D, van der Salm A, Lakeman A, van der Stoep J, Emans D, et al. The PET-boost randomised phase II dose-escalation trial in non-small cell lung cancer. Radiother Oncol 2012; https://doi.org/10.1016/j.radonc.2012.03.005

141.

Yan D, Lockman D, Martinez A, Wong J, Brabbins D, Vicini F, et al. Computed tomography guided management of interfractional patient variation. Semin Radiat Oncol 2005; https://doi.org/10.1016/j.semradonc.2005.01.007

142.

Li XA, Qi XS, Pitterle M, Kalakota K, Mueller K, Erickson BA, et al. Interfractional variations in patient setup and anatomic change assessed by daily computed tomography. Int J Radiat Oncol Biol Phys 2007; https://doi.org/10.1016/j.ijrobp.2006.12.024

143.

Hugo GD, Yan D, Liang J. Population and patient-specific target margins for 4D adaptive radiotherapy to account for intra- and inter-fraction variation in lung tumour position. Phys Med Biol 2007; https://doi.org/10.1088/0031-9155/52/1/017

144.

Mahasittiwat P, Yuan S, Xie C, Ritter T, Cao Y, Ten Haken RK, et al. Metabolic tumor volume on PET reduced more than gross tumor volume on CT during radiotherapy in patients with non-small cell lung cancer treated with 3DCRT or SBRT. Journal of radiation oncology 2013; https://doi.org/10.1007/s13566-013-0091-x

145.

Kong FM, Frey KA, Quint LE, Ten Haken RK, Hayman JA, Kessler M, et al. A pilot study of [18F]fluorodeoxyglucose positron emission tomography scans during and after radiation-based therapy in patients with non small-cell lung cancer. J Clin Oncol 2007; https://doi.org/10.1200/jco.2006.10.3747

146.

Cremonesi M, Gilardi L, Ferrari ME, Piperno G, Travaini LL, Timmerman R, et al. Role of interim (18)F-FDG-PET/CT for the early prediction of clinical outcomes of Non-Small Cell Lung Cancer (NSCLC) during radiotherapy or chemo-radiotherapy. A systematic review. Eur J Nucl Med Mol Imaging 2017; https://doi.org/10.1007/s00259-017-3762-9.

147.

Edet-Sanson A, Dubray B, Doyeux K, Back A, Hapdey S, Modzelewski R, et al. Serial assessment of FDG-PET FDG uptake and functional volume during radiotherapy (RT) in patients with non-small cell lung cancer (NSCLC). Radiother Oncol 2012; https://doi.org/10.1016/j.radonc.2011.07.023

148.

Vera P, Mezzani-Saillard S, Edet-Sanson A, Ménard JF, Modzelewski R, Thureau S, et al. FDG PET during radiochemotherapy is predictive of outcome at 1 year in non-small-cell lung cancer patients: a prospective multicentre study (RTEP2). Eur J Nucl Med Mol Imaging 2014; https://doi.org/10.1007/s00259-014-2687-9

149.

Kong FM, Ten Haken RK, Schipper M, Frey KA, Hayman J, Gross M, et al. Effect of midtreatment PET/CT-adapted radiation therapy with concurrent chemotherapy in patients with locally advanced non-small-cell lung cancer: a phase 2 clinical trial. JAMA Oncol 2017; https://doi.org/10.1001/jamaoncol.2017.0982

150.

Lemjabbar-Alaoui H, Hassan OU, Yang YW, Buchanan P. Lung cancer: Biology and treatment options. Biochim Biophys Acta 2015; https://doi.org/10.1016/j.bbcan.2015.08.002

151.

Thureau S, Chaumet-Riffaud P, Modzelewski R, Fernandez P, Tessonnier L, Vervueren L, et al. Interobserver agreement of qualitative analysis and tumor delineation of 18F-fluoromisonidazole and 3’-deoxy-3’-18F-fluorothymidine PET images in lung cancer. J Nucl Med 2013; https://doi.org/10.2967/jnumed.112.118083

152.

Thureau S, Dubray B, Modzelewski R, Bohn P, Hapdey S, Vincent S, et al. FDG and FMISO PET-guided dose escalation with intensity-modulated radiotherapy in lung cancer. Radiat Oncol 2018; https://doi.org/10.1186/s13014-018-1147-2

153.

Even AJ, van der Stoep J, Zegers CM, Reymen B, Troost EG, Lambin P, et al. PET-based dose painting in non-small cell lung cancer: comparing uniform dose escalation with boosting hypoxic and metabolically active sub-volumes. Radiother Oncol 2015; https://doi.org/10.1016/j.radonc.2015.07.013

154.

Watanabe S, Inoue T, Okamoto S, Magota K, Takayanagi A, Sakakibara-Konishi J, et al. Combination of FDG-PET and FMISO-PET as a treatment strategy for patients undergoing early-stage NSCLC stereotactic radiotherapy. EJNMMI Res 2019; https://doi.org/10.1186/s13550-019-0578-6

155.

Salem A, Asselin MC, Reymen B, Jackson A, Lambin P, West CML, et al. Targeting hypoxia to improve non-small cell lung cancer outcome. J Natl Cancer Inst 2018; https://doi.org/10.1093/jnci/djx160

156.

Zegers CM, van Elmpt W, Wierts R, Reymen B, Sharifi H, Öllers MC, et al. Hypoxia imaging with [¹⁸F]HX4 PET in NSCLC patients: defining optimal imaging parameters. Radiother Oncol 2013; https://doi.org/10.1016/j.radonc.2013.08.031

157.

Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, et al. Durvalumab after chemoradiotherapy in stage III non–small-cell lung cancer. N Engl J Med 2017; https://doi.org/10.1056/NEJMoa1709937

158.

Vera P, Thureau S, Chaumet-Riffaud P, Modzelewski R, Bohn P, Vermandel M, et al. Phase II study of a radiotherapy total dose increase in hypoxic lesions identified by (18)F-misonidazole PET/CT in patients with non-small cell lung carcinoma (RTEP5 study). J Nucl Med 2017; https://doi.org/10.2967/jnumed.116.188367

159.

Vera P, Mihailescu SD, Lequesne J, Modzelewski R, Bohn P, Hapdey S, et al. Radiotherapy boost in patients with hypoxic lesions identified by (18)F-FMISO PET/CT in non-small-cell lung carcinoma: can we expect a better survival outcome without toxicity? [RTEP5 long-term follow-up]. Eur J Nucl Med Mol Imaging 2019; https://doi.org/10.1007/s00259-019-04285-9

160.

Kirchner J, Sawicki LM, Nensa F, Schaarschmidt BM, Reis H, Ingenwerth M, et al. Prospective comparison of 18F-FDG PET/MRI and 18F-FDG PET/CT for thoracic staging of non-small cell lung cancer. Eur J Nucl Med Mol Imaging 2019; https://doi.org/10.1007/s00259-018-4109-x

161.

Lee SM, Goo JM, Park CM, Yoon SH, Paeng JC, Cheon GJ, et al. Preoperative staging of non-small cell lung cancer: prospective comparison of PET/MR and PET/CT. Eur Radiol 2016; https://doi.org/10.1007/s00330-016-4255-0

162.

Schaarschmidt BM, Grueneisen J, Metzenmacher M, Gomez B, Gauler T, Roesel C, et al. Thoracic staging with 18F-FDG PET/MR in non-small cell lung cancer — does it change therapeutic decisions in comparison to 18F-FDG PET/CT? Eur Radiol 2017; https://doi.org/10.1007/s00330-016-4397-0

163.

Sommer G, Stieltjes B. Magnetic resonance imaging for staging of non-small-cell lung cancer-technical advances and unmet needs. J Thorac Dis 2015; https://doi.org/10.3978/j.issn.2072-1439.2015.07.21

164.

Hatt M, Tixier F, Pierce L, Kinahan PE, Le Rest CC, Visvikis D. Characterization of PET/CT images using texture analysis: the past, the present… any future? Eur J Nucl Med Mol Imaging 2017; https://doi.org/10.1007/s00259-016-3427-0

165.

Desseroit MC, Visvikis D, Tixier F, Majdoub M, Perdrisot R, Guillevin R, et al. Development of a nomogram combining clinical staging with (18)F-FDG PET/CT image features in non-small-cell lung cancer stage I-III. Eur J Nucl Med Mol Imaging 2016; https://doi.org/10.1007/s00259-016-3325-5

166.

Lovinfosse P, Janvary ZL, Coucke P, Jodogne S, Bernard C, Hatt M, et al. FDG PET/CT texture analysis for predicting the outcome of lung cancer treated by stereotactic body radiation therapy. Eur J Nucl Med Mol Imaging 2016; https://doi.org/10.1007/s00259-016-3314-8

167.

Oikonomou A, Khalvati F, Tyrrell PN, Haider MA, Tarique U, Jimenez-Juan L, et al. Radiomics analysis at PET/CT contributes to prognosis of recurrence and survival in lung cancer treated with stereotactic body radiotherapy. Sci Rep 2018; https://doi.org/10.1038/s41598-018-22357-y

168.

Visvikis D, Cheze Le Rest C, Jaouen V, Hatt M. Artificial intelligence, machine (deep) learning and radio(geno)mics: definitions and nuclear medicine imaging applications. Eur J Nucl Med Mol Imaging 2019; https://doi.org/10.1007/s00259-019-04373-w.

169.

Hatt M, Parmar C, Qi J, Naqa IE. Machine (Deep) Learning methods for image processing and radiomics. IEEE Transactions on Radiation and Plasma Medical Sciences 2019; https://doi.org/10.1109/TRPMS.2019.2899538

170.

Dissaux G, Visvikis D, Da-Ano R, Pradier O, Chajon E, Barillot I, et al. Pretreatment (18)F-FDG PET/CT radiomics predict local recurrence in patients treated with stereotactic body radiotherapy for early-stage non-small cell lung cancer: a multicentric study. J Nucl Med 2020; https://doi.org/10.2967/jnumed.119.228106

171.

Konert T, van de Kamer JB, Sonke JJ, Vogel WV. The developing role of FDG PET imaging for prognostication and radiotherapy target volume delineation in non-small cell lung cancer. J Thorac Dis 2018; https://doi.org/10.21037/jtd.2018.07.101

172.

Tankyevych O, Tixier F, Antonorsi N, Filali Razzouki A, Mondon R, Pinto-Leite T, et al. Can alternative PET reconstruction schemes improve the prognostic value of radiomic features in non-small cell lung cancer? Methods 2020; https://doi.org/10.1016/j.ymeth.2020.11.002

173.

Reuze S, Schernberg A, Orlhac F, Sun R, Chargari C, Dercle L, et al. Radiomics in nuclear medicine applied to radiation therapy: methods, pitfalls, and challenges. Int J Radiat Oncol Biol Phys 2018; https://doi.org/10.1016/j.ijrobp.2018.05.022

174.

Hatt M, Majdoub M, Vallières M, Tixier F, Le Rest CC, Groheux D, et al. 18F-FDG PET uptake characterization through texture analysis: investigating the complementary nature of heterogeneity and functional tumor volume in a multi-cancer site patient cohort. J Nucl Med 2015; https://doi.org/10.2967/jnumed.114.144055

Title: Joint EANM/SNMMI/ESTRO practice recommendations for the use of 2-[18F]FDG PET/CT external beam radiation treatment planning in lung cancer V1.0
Authors: Sofia C. Vaz
Judit A. Adam
Roberto C. Delgado Bolton
Pierre Vera
Wouter van Elmpt
Ken Herrmann
Rodney J. Hicks
Yolande Lievens
Andrea Santos
Heiko Schöder
Bernard Dubray
Dimitris Visvikis
Esther G. C. Troost
Lioe-Fee de Geus-Oei
Publication date: 01-03-2022
Publisher: Springer Berlin Heidelberg
Keywords: NSCLC
Lung Cancer
Lung Cancer
NSCLC
SCLC
Radiotherapy
Positron Emission Tomography
Lung Cancer
SCLC
Published in: European Journal of Nuclear Medicine and Molecular Imaging / Issue 4/2022
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-021-05624-5

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Joint EANM/SNMMI/ESTRO practice recommendations for the use of 2-[¹⁸F]FDG PET/CT external beam radiation treatment planning in lung cancer V1.0

Abstract

Purpose

Methods

Results and conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results and conclusion

Please log in to get access to this content

Other articles of this Issue 4/2022

18F-florbetapir PET as a marker of myelin integrity across the Alzheimer’s disease spectrum

Somatostatin receptor imaging with [68Ga]Ga-DOTATATE positron emission tomography/computed tomography (PET/CT) in patients with nasopharyngeal carcinoma

PET/CT imaging of head-and-neck and pancreatic cancer in humans by targeting the “Cancer Integrin” αvβ6 with Ga-68-Trivehexin

Mapping covariance in brain FDG uptake to structural connectivity

EANM position on the in-house preparation of radiopharmaceuticals

PET imaging of reactive astrocytes in neurological disorders